We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

By LabMedica International staff writers
Posted on 23 Nov 2023
Print article
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body. Identifying sepsis early is crucial, and one key indicator is the elevated presence of immature granulocytes (IGs), which have been shown to signal sepsis earlier than other common measures such as lactate and procalcitonin levels. Additionally, the neutrophil-to-lymphocyte ratio (NLR) has emerged as a vital predictor of adverse health outcomes, especially noted during the recent pandemic. Now, a rapid-result hematology system capable of delivering these vital diagnostic measures almost instantaneously has the potential to revolutionize patient care.

Ad Astra Diagnostics (Morrisville, NC, USA) has introduced the QScout rapid-result hematology system, a groundbreaking platform that provides quick, point-of-care white blood cell counts (WBCs), NLR, and accurately differentiates between five types of mature WBCs and IGs. QScout stands out as the first hematology platform designed for easy, rapid use at the point of care. It delivers lab-quality results right beside the patient, aiding in screening for various health conditions including infections, leukemia, other blood cancers, allergies, and more.

The QScout RLD test is notably the first to provide point-of-care reporting of infection-fighting IGs and NLR. To administer the test, whole blood is applied to the QScout RLD test, which contains a specialized dried reagent for staining cells. When placed into the QScout Lab analyzer, an advanced optical system captures images, and a sophisticated algorithm identifies cells in real-time. The process delivers results within approximately two minutes. Remarkably, QScout requires no extensive startup time or sample preparation, no liquid reagents for change or disposal, and no pumps. The system can be activated and ready to deliver initial results in around three minutes and is designed for simple operation with minimal training. Ad Astra has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its innovative QScout rapid-result hematology system.

"QScout uses a cutting-edge imaging-based system not prone to the challenges of flow cytometry, which means that cells are examined directly by an AI-trained system instead of indirect measures like light scatter or electrical resistance," said Jasper Pollard, Chief Technology Officer, Ad Astra Diagnostics. "With this 510(k) clearance, we move closer to bringing our innovative diagnostic platform to various point-of-care settings, where faster results can improve health outcomes, and to labs, where it can improve efficiency and operations."

"Achieving 510(k) clearance for the QScout platform is a momentous step for our AAD team, and we believe it will be the first of many positive interactions with the FDA," said Joy Parr Drach, AAD's President & CEO. "In developing QScout, we aim to enable and democratize rapid, point-of-care decision-making, and we are confident that its simple, easy-to-use, rugged, no maintenance design has the potential to be an invaluable tool in a variety of healthcare settings."

Related Links:
Ad Astra Diagnostics 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.